Advertisement
New Zealand markets closed

  • NZX 50

    11,820.78
    -117.30 (-0.98%)
     

  • NZD/USD

    0.6020
    +0.0008 (+0.14%)
     

  • ALL ORDS

    7,952.30
    +54.80 (+0.69%)
     

  • OIL

    78.99
    +0.88 (+1.13%)
     

  • GOLD

    2,327.50
    +18.90 (+0.82%)
     

Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics

Zacks Equity Research
·2-min read

PTC Therapeutics (PTCT) reported $210.12 million in revenue for the quarter ended March 2024, representing a year-over-year decline of 4.7%. EPS of -$1.20 for the same period compares to -$1.88 a year ago.

The reported revenue represents a surprise of +31.10% over the Zacks Consensus Estimate of $160.27 million. With the consensus EPS estimate being -$1.21, the EPS surprise was +0.83%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

ADVERTISEMENT

Here is how PTC Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenues- Net product revenue: $177.60 million versus $115.73 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -5.3% change.

  • Revenues- Royalty revenue: $31.15 million versus the five-analyst average estimate of $39.73 million. The reported number represents a year-over-year change of +1.1%.

  • Revenues- Net product revenue- Translarna: $103.60 million versus the four-analyst average estimate of $47.69 million. The reported number represents a year-over-year change of -10%.

  • Revenues- Net product revenue- Emflaza: $57.50 million versus the four-analyst average estimate of $52.06 million. The reported number represents a year-over-year change of +5.3%.

View all Key Company Metrics for PTC Therapeutics here>>>

Shares of PTC Therapeutics have returned -14.4% over the past month versus the Zacks S&P 500 composite's -3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

PTC Therapeutics, Inc. (PTCT) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research